NOT FOR DISTRIBUTION
Header cover image

China Isotope & Radiation

Market Cap

HK$8.8b

Last Updated

2021/04/19 10:11 UTC

Data Sources

Company Financials +

Executive Summary

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. More Details


Snowflake Analysis

High growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has China Isotope & Radiation's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1763 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 1763's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

1.6%

1763

-1.2%

HK Medical Equipment

0.7%

HK Market


1 Year Return

58.0%

1763

43.4%

HK Medical Equipment

28.1%

HK Market

Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned 43.4% over the past year.

Return vs Market: 1763 exceeded the Hong Kong Market which returned 28.1% over the past year.


Shareholder returns

1763IndustryMarket
7 Day1.6%-1.2%0.7%
30 Day13.0%6.1%-0.2%
90 Day11.9%-5.6%0.2%
1 Year59.0%58.0%45.0%43.4%33.4%28.1%
3 Yearn/a208.5%194.3%8.1%-3.8%
5 Yearn/a293.6%258.6%56.5%28.9%

Long-Term Price Volatility Vs. Market

How volatile is China Isotope & Radiation's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Isotope & Radiation undervalued compared to its fair value and its price relative to the market?

34.94x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1763 (HK$27.8) is trading above our estimate of fair value (HK$3.88)

Significantly Below Fair Value: 1763 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1763 is poor value based on its PE Ratio (34.9x) compared to the HK Medical Equipment industry average (29.9x).

PE vs Market: 1763 is poor value based on its PE Ratio (34.9x) compared to the Hong Kong market (11.8x).


Price to Earnings Growth Ratio

PEG Ratio: 1763 is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: 1763 is good value based on its PB Ratio (1.9x) compared to the HK Medical Equipment industry average (3x).


Future Growth

How is China Isotope & Radiation forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

33.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1763's forecast earnings growth (33.9% per year) is above the savings rate (1.5%).

Earnings vs Market: 1763's earnings (33.9% per year) are forecast to grow faster than the Hong Kong market (18.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1763's revenue (20.4% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).

High Growth Revenue: 1763's revenue (20.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1763's Return on Equity is forecast to be low in 3 years time (13.6%).


Past Performance

How has China Isotope & Radiation performed over the past 5 years?

-0.08%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1763 has high quality earnings.

Growing Profit Margin: 1763's current net profit margins (5%) are lower than last year (8.2%).


Past Earnings Growth Analysis

Earnings Trend: 1763's earnings have declined by 0.08% per year over the past 5 years.

Accelerating Growth: 1763's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1763 had negative earnings growth (-35%) over the past year, making it difficult to compare to the Medical Equipment industry average (19.7%).


Return on Equity

High ROE: 1763's Return on Equity (8.6%) is considered low.


Financial Health

How is China Isotope & Radiation's financial position?


Financial Position Analysis

Short Term Liabilities: 1763's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥2.8B).

Long Term Liabilities: 1763's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥907.5M).


Debt to Equity History and Analysis

Debt Level: 1763's debt to equity ratio (12%) is considered satisfactory.

Reducing Debt: 1763's debt to equity ratio has increased from 4.6% to 12% over the past 5 years.

Debt Coverage: 1763's debt is well covered by operating cash flow (44%).

Interest Coverage: 1763 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is China Isotope & Radiation current dividend yield, its reliability and sustainability?

0.77%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 20 2021Ex Dividend DateMay 17 2021Dividend Pay DateJul 26 202170 days from Ex DividendBuy in the next 27 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 1763's dividend (0.77%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.95%).

High Dividend: 1763's dividend (0.77%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.98%).


Stability and Growth of Payments

Stable Dividend: 1763 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.

Growing Dividend: 1763 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 1763 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1763's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

China Isotope & Radiation has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 1763's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: 1763's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Isotope & Radiation Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Isotope & Radiation Corporation
  • Ticker: 1763
  • Exchange: SEHK
  • Founded: 1983
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: HK$8.797b
  • Shares outstanding: 319.87m
  • Website: https://www.circ.com.cn

Number of Employees


Location

  • China Isotope & Radiation Corporation
  • Building 1
  • No. 66 Changwa Middle Street
  • Beijing
  • Beijing Province
  • 100089
  • China

Listings


Biography

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and indus...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/19 10:11
End of Day Share Price2021/04/19 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.